Catalent Announces New Optimized Drug Delivery Technologies at CPhl Worldwide/ICSE

New Technologies for Deterring Abuse, Providing Oral Alternatives to Injectable Delivery, Improving Compliance and Improving Patient Experience Launched in Frankfurt

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This

Somerset, NJ & CPhI Worldwide/ICSE, Frankfurt, Germany (PRWEB) October 23, 2013

Catalent Pharma Solutions, the global leader in development solutions and advanced delivery technologies for drug, biologic and consumer health products, today announced that it is introducing several new drug delivery technologies at CPhI Worldwide/ICSE (Messe Frankfurt, Frankfurt, Germany 21-24 October 2013, Hall 4.2), all of which may offer delivery solutions and important IP advantages to drug manufacturers.

Catalent announced two new RP Scherer Softgel offerings to help develop more molecules into better treatments for patients. The first, OptiGel Lock™, is designed to prevent the abuse of prescription pain medications, and the deliberate misuse of consumer pseudoephedrine products. Developed in response to regulatory demands for alternative technologies that might deter abuse, this new softgel delivery technology incorporates several levels of deterrent into a single formulation designed to prevent extraction of the active substance.

Also new is OptiGel Bio™, which may enable certain macromolecules to be delivered orally and overcome permeability and stability challenges in a more easily administered form than injection. OptiGel Bio may improve the permeability of large molecule APIs, while also enabling targeted delivery to be achieved via an enteric coating. This protective coating eliminates degradation of the encapsulated formulation in the stomach. Patient advantages may include reduced dosing complexity, improved safety and better adherence.

Finally, OptiGel Mini™ technology enables the creation of capsules that are approximately 30% smaller and yet accommodate the same amount of active ingredients as conventional softgel capsules, providing a substantial benefit over many prescription and consumer health products and making them easier for the patient or consumer to swallow. Following the recent introduction of OptiShell™ technology, to provide solutions for complex semi-solid lipid-based formulations, Catalent continues to innovate by delivering advanced drug delivery technologies, bioavailability solutions and versatile and proven softgel technologies.

In addition, Catalent announced two new technologies under its proprietary Zydis® Oral Fast Dissolve Technology platform. Zydis Bio™ may help deliver large molecules such as proteins, peptides, viral vaccines and allergens in a patient preferred oral fast dissolve format in as little as three seconds. Zydis Nano™ technology is designed to improve bioavailability of compounds in a fast dissolve format.

Catalent will also be discussing new OSDrC® OptiDose™ advanced tableting technology for multiple release profiled (pulsatile, immediate release and extended release ) and combination products at CPhI, as well as its next generation antibody drug conjugation (ADC) technology for Biologics – SMARTag™.

“These innovations underline Catalent’s commitment to constantly bringing new products to market faster, with the ultimate goal of providing better treatments to patients, in the most effective manner,” commented Kurt Nielsen, Senior Vice President, Catalent R&D. “Whether deterring substance abuse, providing an alternative to injection, or improving compliance and adherence, our new technologies deliver significant benefits to developers, marketers and end users.”

About Catalent

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 8,500 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.7 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™


Contact

  • Richard Kerns
    Northern Exposure PR
    +44 (0) 7974 579202
    Email